# Mark C. McKenna

> Mark C. McKenna is the founder, chairman and CEO of Mirador Therapeutics. He previously led Prometheus Biosciences through its 2023 acquisition by Merck for $10.8 billion, after a commercial leadership career at Johnson & Johnson, Bausch + Lomb and Salix Pharmaceuticals. He also holds investment and board roles and, with his wife Sheri, supported a new interdisciplinary program at Arizona State University.

- **Role:** Founder, Chairman & CEO at Mirador Therapeutics
- **Organizations:** Mirador Therapeutics, Prometheus Biosciences, Salix Pharmaceuticals, Bausch + Lomb, Johnson & Johnson, Apogee Therapeutics, Spyre Therapeutics, NewAmsterdam Pharma, ARCH Venture Partners, Fairmount Funds Management, McKenna Capital Partners
- **Education:** B.S. in Marketing, Arizona State University, MBA, Azusa Pacific University, Wharton Fellows Program (executive education), The Wharton School, University of Pennsylvania
- **Known for:** Led Prometheus through its $10.8 billion acquisition by Merck in June 2023., Raised more than $1 billion in private and public financing while leading Prometheus., Launched Mirador with more than $400 million in financing in March 2024.

## Career timeline

- **2002** — Graduated from ASU and began his career at Johnson & Johnson.
- **Before 2016** — Spent more than a decade at Bausch + Lomb, ultimately serving as SVP and general manager of U.S. Vision Care.
- **2016-2019** — President of Salix Pharmaceuticals from March 2016 through August 2019.
- **2019-2023** — President and CEO of Prometheus Biosciences from September 2019 through June 2023; chairman from August 2021.
- **2023** — Merck completed the $10.8 billion Prometheus acquisition in June; became Apogee chairman in August.
- **2024** — Became ARCH venture partner and Spyre director in February; launched Mirador in March; joined NewAmsterdam board in July.
- **2025** — Mark and Sheri McKenna supported the establishment of ASU’s McKenna Life Sciences, Business and Entrepreneurship Program.
- **2026** — Mirador announced $250 million Series B financing closed in Q3 2025; total funding exceeded $650 million.

## Achievements

- Led Prometheus through its $10.8 billion acquisition by Merck in June 2023.
- Raised more than $1 billion in private and public financing while leading Prometheus.
- Launched Mirador with more than $400 million in financing in March 2024.
- Recipient of the EY Entrepreneur Of The Year 2023 Pacific Southwest Award.
- Recipient of the 2025 ASU Alumni Achievement Award.
- Supported an ASU interdisciplinary degree program with Sheri McKenna.

## Latest updates

- **2026-07** — Mirador announced an exclusive worldwide license agreement with Kira Pharmaceuticals, expanding its portfolio.
- **2026-05** — ASU published McKenna’s reflections on his career and ambitions for the McKenna program.
- **2026-04** — ASU announced McKenna as its May undergraduate business convocation speaker and said the program would welcome its first cohort in fall 2026.
- **2026-01** — Mirador disclosed its $250 million Series B, completed in Q3 2025, bringing total capital raised above $650 million.

## Links

- Website: https://www.miradortx.com/

---

Profile page: https://yespress.io/mark-mckenna
Published by YesPress — https://yespress.io
Last updated: 2026-10-08